Genovis Q3 2024: Initial take – Stronger than anticipated - Redeye
Redeye provides its initial take on Genovis' Q3 report, which exceeded expectations across the board. We anticipate a positive relief in the share price, accompanied by upward estimate revisions following today's report.
ANNONS
Redeye provides its initial take on Genovis' Q3 report, which exceeded expectations across the board. We anticipate a positive relief in the share price, accompanied by upward estimate revisions following today's report.